MedTrace Logo

Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19

NCT04486001 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-03-17

No results posted yet for this study

Summary

This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic environment. This data will be used for FDA IND filings and pursuit of a BLA.

Conditions

  • Covid19

Interventions

BIOLOGICAL

PSC-04

adipose stem cells derived from screened donor lipoaspirate and culture expanded.

Sponsors & Collaborators

  • VetStem Biopharma, Inc.

    collaborator UNKNOWN

  • Fresno Community Hospital and Medical Center

    collaborator OTHER

  • Sorrento Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mike Royal, MD JD · Sorrento Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2021-06-09
Completion
2021-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04486001 on ClinicalTrials.gov